{"entity":{"id":"nct06627712","kind":"trial","name":"SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC","aka":[],"tldr":"A phase 3 trial in triple-negative breast cancer, run by West China Hospital, now recruiting.","summary":"SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC is a phase 3, randomised interventional study registered as NCT06627712 by West China Hospital, with a registry enrolment figure of 318 participants, started 2024-11-01 and due to reach its primary completion in 2029-11-01. Interventions recorded: SBRT+PD-1 Inhibitor + Chemotherapy; PD-1 Inhibitor + Chemotherapy. Conditions listed: TNBC - Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Histologically or cytologically confirmed TNBC (ER-, PR-, HER2-)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06627712","url":"https://clinicaltrials.gov/study/NCT06627712"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06627712","phase":"3","setting":"Stereotactic Body Radiotherapy (SBRT) Combined With PD-1 Inhibitor and Chemotherapy in Early-stage Treatment-naive Triple-negative Breast Cancer Patients: A Multicenter Phase III Clinical Study","sponsor":"West China Hospital","enrolled":318,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06627712/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}